In patients with breast cancer, T cell p16INK4a expression was positively associated with peripheral neuropathy after 1.5 years of treatment with paclitaxel and docetaxel [50], and fatigue after one month of taxane-based chemotherapy [51]. Here, CDKN2A is linked to peripheral neuropathy.